Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Y Chan

Showing results (341-350 of 371) with videos related to

Pageof 38
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Genome Research|February 28, 2019
Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of originKun Sun, Peiyong Jiang, Suk Hang Cheng, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Nature Communications|December 10, 2022
The establishment of COPD organoids to study host-pathogen interaction reveals enhanced viral fitness of SARS-CoV-2 in bronchiLouisa L Y Chan, Danielle E Anderson, Hong Sheng Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingK C Allen Chan, Peiyong Jiang, Carol W M Chan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2016
Critical Role of Antimicrobial Peptide Cathelicidin for Controlling Helicobacter pylori Survival and InfectionLin Zhang, William K K Wu, Richard L Gallo, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BYoung-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Pageof 38

Showing results (341-350 of 371) with videos related to

Sort By:
Pageof 38
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Genome Research|February 28, 2019
Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of originKun Sun, Peiyong Jiang, Suk Hang Cheng, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Nature Communications|December 10, 2022
The establishment of COPD organoids to study host-pathogen interaction reveals enhanced viral fitness of SARS-CoV-2 in bronchiLouisa L Y Chan, Danielle E Anderson, Hong Sheng Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingK C Allen Chan, Peiyong Jiang, Carol W M Chan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2016
Critical Role of Antimicrobial Peptide Cathelicidin for Controlling Helicobacter pylori Survival and InfectionLin Zhang, William K K Wu, Richard L Gallo, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BYoung-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Pageof 38